Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Cuong Viet Do
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Beta
- 0.67
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -39.35
Financials
Net Income
$-5.65MEBITDA
$-5.71MFree Cash Flow
$-4.12MEPS (diluted)
$-0.75Shares Outstanding (diluted)
7.54M+108022.7%Operating Expenses
$5.71MCash & Debt
$8.98MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-22.07M | $-3.05 |
| 2025 | $0.00 | $-17.54M | $-12.12 |
| 2024 | $0.00 | $-32.12M | $-73.05 |
| 2023 | $0.00 | $-50.26M | $-154.70 |
| 2022 | $0.00 | $-26.08M | $-106.00 |
| 2021 | $0.00 | $-130.25M | $-1482.30 |
| 2020 | $0.00 | $-16.68M | $-685.20 |
| 2019 | $0.00 | $-2.44M | $-98.20 |
| 2018 | $0.00 | $-2.41M | $-317.70 |
| 2017 | $0.00 | $-1.33M | $-186.10 |
| 2016 | $0.00 | $-431.9K | $-61.90 |
| 2015 | $0.00 | $-233.0K | $-33.40 |
| 2014 | $0.00 | $-321.9K | $-46.20 |
| 2013 | $0.00 | $-70.0K | $-0.21 |
Valuation
BIVIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
65-7.14%Social Signal Score
Mentions (9)
- Newsseekingalpha.com·12d ago·Positive
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
View source ↗ - Newsseekingalpha.com·20d ago·Positive
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
View source ↗ - Newsglobenewswire.com·21d ago·Positive
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID Statistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise
View source ↗ - Newsglobenewswire.com·21d ago·Positive
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)
View source ↗ - Newsproactiveinvestors.com·28d ago·Negative
BioVie advances Parkinson's Phase 3 development program with FDA engagement BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
BioVie Announces Update to Parkinson's Phase 3 Development Program Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease
View source ↗ - Newsproactiveinvestors.com·36d ago·Positive
BioVie completes final patient visit in Phase 2 Long COVID trial BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.
View source ↗ - Newsglobenewswire.com·36d ago·Negative
…C Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Typical surprise +4.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.70 vs $-0.52miss
- Mon, May 11$-0.70 vs $-0.73beat
- Tue, Feb 10$-0.77 vs $-0.81beat
- Mon, Nov 10$-0.98 vs $-0.79miss
- Fri, Aug 15$-1.82 vs $-1.82beat
- Mon, May 12$-1.50 vs $-3.20beat
Estimates and results for BIVI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIVI officers and directors.
- Bought
- $4.0m
- Sold
- $353k
11 trades
8 trades
- Palumbo Joseph Mbought
- Chappell Amy Suzonbought
- Kim Joanne Wendybought
- Do Cuong Vbought
- Do Cuong Vbought
- Do Cuong Vbought
- Do Cuong Vbought
- Do Cuong Vbought
81 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BIVI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.